OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Hematology is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Hematological findings and complications of COVID‐19	1204
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management	481
Hematologic parameters in patients with COVID‐19 infection	326
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination	307
Thrombosis in COVID‐19	217
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring	207
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management	198
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management	183
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	178
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures	141
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies	136
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management	135
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine	124
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management	113
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis	112
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy	104
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA	101
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management	99
Morphological anomalies of circulating blood cells in COVID‐19	95
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure	95
Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment	93
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study	89
Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine	89
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center	87
Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab	81

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients	80
Critically ill COVID‐19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability	76
Acute myeloid leukemia: 2021 update on risk‐stratification and management	72
Leukoerythroblastic reaction in a patient with COVID‐19 infection	70
Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19)	67
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management	66
POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management	65
Marked factor V activity elevation in severe COVID‐19 is associated with venous thromboembolism	65
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring	64
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab	64
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY	64
Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management	64
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation	60
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma	60
COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient	57
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality	57
COVID‐19 and mycoplasma pneumoniae coinfection	55
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment	52
Hepcidin levels predict Covid‐19 severity and mortality in a cohort of hospitalized Italian patients	51
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients	50
Recommendations for diagnosis and treatment of methemoglobinemia	50
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management	50
Dramatic improvement after tocilizumab of severe COVID‐19 in a child with sickle cell disease and acute chest syndrome	50
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1	49